Understand what your immune health results really mean
See your biomarkers in context with a comprehensive panel.
- CLIA-certified labs
- HIPAA compliant
- Personalized health protocol
Inflammatory bowel disease and the blood markers that track it
IBD biomarkers are measurable signals from your immune system and gut that reveal when and how much inflammation is present in Crohn’s disease or ulcerative colitis. They translate invisible intestinal activity into objective information your care team can track, reducing guesswork and complementing symptoms and scans. Blood tests reflect whole-body inflammation and its ripple effects: a liver-made alarm protein (C-reactive protein), the rate red cells settle when inflammation is active (erythrocyte sedimentation rate), shifts in white cells and platelets (leukocytes, thrombocytes), anemia and iron status (hemoglobin, ferritin), and nutrition status (albumin). Stool testing adds a gut-specific readout from neutrophils at the bowel wall (fecal calprotectin). Together, these markers help distinguish IBD from look-alike conditions, gauge disease activity, anticipate flares, guide treatment choice and dosing, and monitor healing—often reducing the need for urgent endoscopy. Biologically, they arise from three places: liver acute-phase responses, immune-cell products, and proteins leaking from an injured intestinal barrier. Watching their patterns over time shows whether inflammation is quieting or smoldering, enabling timely, targeted care that protects the bowel.
Why bloodwork matters in IBD
Blood tests for IBD track how active inflammation is—and how it’s affecting the whole body. Inflammatory signals don’t stay in the gut; they alter liver protein production, clotting balance, nutrition status, and immune tone. These biomarkers help distinguish a quiet bowel from a brewing flare, and reveal extra‑intestinal impact on energy, growth, and recovery. CRP is an acute‑phase protein that typically sits under 3 in health (many labs accept under 5–8). ESR in healthy adults is often under 20, trending higher with age and in women. Albumin, a liver‑made carrier protein, usually runs 3.5–5.0, with optimal health toward the middle‑to‑higher end. Ratios such as FAR (fibrinogen‑to‑albumin) and CAR (CRP‑to‑albumin) have no universal reference ranges, but lower values generally indicate low inflammatory burden. When CRP and ESR are low, it suggests mucosal inflammation is minimal and systemic cytokine signaling is quiet—people tend to feel clearer, with steadier energy and fewer fevers or night sweats. By contrast, low albumin often reflects protein loss from an inflamed gut, poor intake, or catabolism, and can show up as swelling, muscle loss, slow wound healing, and in children, slowed growth. Pregnancy physiologically lowers albumin and can raise CRP; ESR runs higher with age and in women, so context matters. Low FAR and CAR are reassuring; higher values point to more active inflammation and catabolic stress, often paralleling abdominal pain, diarrhea, bleeding, and weight loss. Big picture, these markers integrate immune activity with liver synthesis, vascular inflammation, and nutrition—systems that shape bone health, anemia risk, clotting tendency, and long‑term complications of IBD. Regular measurement helps map disease trajectory and whole‑body impact over time.
Test 100+ biomarkers from home
One blood draw. A full picture of your health, explained in plain language.
Test 100+ biomarkers from home
One blood draw. A full picture of your health, explained in plain language.
What inflammatory markers show and what they miss
Inflammatory bowel disease (IBD) blood testing provides a window into how inflammation is affecting your body’s core systems—immunity, metabolism, nutrient absorption, and even energy production. Chronic inflammation in IBD can disrupt these interconnected processes, impacting everything from cardiovascular health to cognitive function. At Superpower, we measure five key biomarkers: C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), albumin, fibrinogen-to-albumin ratio (FAR), and CRP-to-albumin ratio (CAR). CRP and ESR are markers of systemic inflammation. CRP rises quickly in response to inflammation, while ESR reflects more gradual changes. Both are commonly elevated during IBD flares, signaling active immune system engagement. Albumin is a major blood protein produced by the liver; low levels can indicate inflammation, poor nutrition, or protein loss through the gut, all of which are concerns in IBD. FAR and CAR are calculated ratios that combine these markers, offering a more nuanced view of inflammation and protein status. When these biomarkers are within healthy ranges, it suggests that inflammation is controlled, the immune system is stable, and the body’s protein reserves are adequate—key factors for maintaining gut integrity and overall resilience in IBD. Shifts outside the expected range can signal increased disease activity or complications, reflecting how well your body is coping with the demands of chronic inflammation. Interpretation of these results depends on context. Factors like age, pregnancy, recent infections, other illnesses, medications, and even laboratory methods can influence these markers. Results should always be considered alongside your clinical history and symptoms.
Frequently Asked Questions
References
- Mosli MH, Zou G, Garg SK, Feagan SG, MacDonald JK, Chande N, Sandborn WJ, Feagan BG (2015). C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: A systematic review and meta-analysis. *The American Journal of Gastroenterology*, *110*(6), 802-819. https://doi.org/10.1038/ajg.2015.120
- Rubin DT, Ananthakrishnan AN, Siegel CA, Barnes EL, Long MD (2025). ACG clinical guideline update: Ulcerative colitis in adults. *The American Journal of Gastroenterology*, *120*(6), 1187-1224. https://doi.org/10.14309/ajg.0000000000003463
- Lichtenstein GR, Loftus EV, Afzali A, Cohen RD (2025). ACG clinical guideline: Management of Crohn's disease in adults. *The American Journal of Gastroenterology*, *120*(6), 1225-1264. https://doi.org/10.14309/ajg.0000000000003465
- Vermeire S, Van Assche G, Rutgeerts P (2004). C-reactive protein as a marker for inflammatory bowel disease. *Inflammatory Bowel Diseases*, *10*(5), 661-665. https://doi.org/10.1097/00054725-200409000-00026
- National Institute of Diabetes and Digestive and Kidney Diseases. (2024). *Crohn's disease*. https://www.niddk.nih.gov/health-information/digestive-diseases/crohns-disease
